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IONIC CONDUCTIVITY IN NON-IONIC COMPOUNDS 
Usha Kranthi Avala                           August 2013                        67 Pages 
Directed By: Dr. Quentin Lineberry, Dr. Yan Cao, and Dr. Stuart Burris    
Department of Chemistry                                  Western Kentucky University 
 The main objective of this work is to investigate the ionic conductivity of the drugs 
under certain conditions and also to compare the ionic conductivities of drugs determined 
by single surface sensors and parallel plate sensors. The ionic conductivity of various 
materials at their pre-melt and melt states are studied in order to further study a recently 
discovered phenomenon. Polar solids like Lidocaine, Ketoconazole, Procainamide and 
Nifedipine were examined in this study. Experimental studies show an increase in ionic 
conductivity in both pre-melt (20 -30 °C below melting temperature) and melt transition 
regions. Results of ionic conductivity of both parallel plate and single surface sensor at 
different frequencies are compared. At 1000 Hz, all the samples show an increase in ionic 
conductivity with both parallel plate and single surface sensor, but at 0.1 Hz frequency, 
no increase in ionic conductivity is observed with parallel plate sensor except for 
Nifedipine.  
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I. INTRODUCTION 
 
A. Thermal Analysis 
Thermal analysis is a collection of techniques that measure the properties of a 
material as a function of temperature. It is useful in measuring different physical 
properties, thermal transitions, and chemical reactions of sample materials as a function 
of temperature, heating rate, and time
1
. The most commonly used thermal analytical 
techniques in the characterization of pharmaceuticals are thermogravimetric analysis 
(TGA) for weight loss or gain, differential scanning calorimetry (DSC) for heat flow, and 
dielectric analysis (DEA) for ionic conductivity and dielectric properties
2
. DEA and DSC 
are material characterization techniques that can analyze a wide variety of solids, liquids, 
and polymers. These techniques are fast, reliable and employ small amounts of samples 
for analysis. Materials like acetanilide, anthracene, polyethylene, and nylon 6 were 
evaluated using DSC and DEA which revealed unique ionic conductivity behavior of 
materials
2, 3
.
 
DEA uniquely measures dielectric properties of the materials which reveal 
physico-chemical properties of the drug under testing
3
. 
DEA employs parallel plate or an interdigitated array of electrodes for 
measurement of two fundamental properties of the material, as a function of frequency, 
time, and temperature
4
.
 
The capacitance property is defined as the ability of the material 
to store the charge; conductance is the ability to transfer the charge. When the material is 
heated above its melting point, conductive properties become important, but at low 
temperatures, the capacitive property dominates. At higher temperatures, the dipoles can 
align themselves in the direction of the electric field which allows measuring the current, 
due to which conductive property dominates at higher temperatures
5
.
 
The electrical 
 2 
 
properties evaluated by DEA use a wide range of frequencies ranging from 0.1Hz to 
100,000Hz and wide temperature range depending on the model of instrument
5
.     
DEA measures three important quantities: Tan delta, loss factor, and permittivity. 
Permittivity, denoted by е', is a measure of the alignment of the dipoles to the electric 
field and is proportional to capacitance. Loss factor, denoted by е'', is energy required to 
align dipoles in the direction of electric field and also to move ions. Loss factor is 
proportional to conductance
6
. Tan delta is the ratio of the loss factor to permittivity. After 
heating, when the material starts to melt, the ability for movement of dipoles increases 
which then increases the ionic conductivity of the material. DSC allows measuring the 
heat flow through the sample and certain other physical properties of the material like 
melting and crystallization temperatures
6
.
 
TGA studies reveal degradation of the drug and 
its stability. Thus, TGA, DSC, and DEA were used to characterize the samples which 
have different roles in pharmaceutical industry. 
 
B. Pharmaceuticals 
Pharmaceutical drugs may be polar or non-polar in nature. In polar drugs the 
electron density is not symmetrically distributed within the drug which leads to existence 
of positive and negative dipoles
7
.
 
Water is a good example of a polar compound. In non-
polar drugs there is symmetrical distribution of electron density which makes them 
insoluble in water.  One of the ways to increase the solubility of non-polar drugs is 
converting them into ionized forms
8
. The
 
polar nature of the drug affects its 
bioavailability. A drug must be relatively non-polar to cross some membranes in the 
body. If a drug is too non-polar, it affects its bioavailability by binding too tightly to 
 3 
 
proteins or food components. Pharmaceutical drugs can be modified into an ionisable 
form known as a pharmaceutical salt
9
. These forms are generally used when the parent 
drug is chemically unstable, difficult for administration, or due to its pharmacokinetic 
profile like improper absorption. More than one salt form of a drug can be produced in 
the market, but they are considered therapeutically equivalent. The ionized form of the 
drug is more polar and more soluble than the parent drug
10
. The drug, which is known as 
the active pharmaceutical ingredient (API) is mixed with excipients in the formulations. 
These excipients not only fill up the amount in formulations but also play a role in drug 
properties like dissolution and bioavailability. The dielectric properties of the medium 
also play an important role in the solubility of the drug. At higher dielectric constant, the 
drug is converted into more ionized form which increases its solubility. All these 
properties are considered before formulation of any drug
11
. 
 C. Instrumentation  
Thermal analytical instruments like DEA, TGA and DSC require a small amount 
of sample for analysis. Due to this reason, these techniques play a major role in chemical 
industries. DEA provides information about the dielectric properties along with the ionic 
conductivity of the sample with respect to time, temperature and frequency. DSC 
measures properties like melting temperature and crystallization temperature of the 
sample with respect to time and temperature
1
. TGA measures the weight loss or gain with 
respect to time and temperature. 
1. Dielectric Thermal Analysis 
DEA is used to analyze various materials like gels, thin films, solids, powders, 
and liquids. Because of this, it is used in various chemical industries. Dielectric analysis 
 4 
 
is a technique used to measure ionic response of a material with respect to temperature, 
frequency and time
1
. The dielectric analyzer is frequency-dependent electrical response 
where the sample is exposed to alternating electric field (sinusoidal voltage) by placing it 
on a single surface gold ceramic interdigitated sensor or on a gold plated parallel plate 
sensor. This electric field produces polarization within the sample which causes the 
dipoles to oscillate with same frequency as that of the electric field but with small shift in 
phase angle (δ), see Figure 1. The comparison between the applied voltage and measured 
current gives the shift in phase angle
16
. DEA measures the structural relaxation and 
molecular motions present in a sample.  As long as dipole moments are present in a 
sample, it allows the measurement of secondary relaxations using DEA
5
. Secondary 
relaxations are those movements which are active in the bulk of the sample. The 
measurement of dielectric properties of the drug is due to mobility of dipoles within the 
drug sample. Ionic conductivity is generally seen in polar drugs rather than non-polar 
drugs. Sometimes, ionic conductivity is also seen in non-polar drugs. Ionic conductivity 
in non-polar drugs is usually due to the presence of polar impurities which exhibit ionic 
conductivity
6
. Polarization is faster when the sample is in a liquid state, as the liquid state 
has higher mobility for the ions when compared to the solid state. Therefore, the samples 
of higher amorphous content have higher polarization, which increases ionic 
conductivity. 
 DEA measures the two fundamental electrical characteristics of a material as a 
function of time, temperature, and frequency. These properties are contradictory to each 
other where capacitance is the ability of a sample to store electrical charge and 
conductance is the ability to conduct or transfer electrical charge in the sample
6
. In 
 5 
 
viscous samples, the ions have ease of mobility under the applied electric field. This 
increases ionic conductivity within the sample. The properties of the sample like 
molecular mobility, response time to an electric field, and polarization time of the sample 
are given by tan delta values. The time taken for the dipoles to align in the direction of 
the field is known as polarization time or relaxation time
12
. The current measured is 
divided into capacitance and conductance. Information about chemical and rheological 
properties like molecular movement and polarization in the drug and polymers is given 
by molecular mobility of the sample which in turn relates to capacitance and 
conductance
12
. The sample is placed between the electrodes, and an alternating electric 
field is applied which creates polarization in the sample which leads to oscillation in 
dipoles in the same frequency but with shift in phase angle δ as seen in Figure 113. 
Capacitance, which is related to induced dipoles and alignment of dipoles, is given by 
measurement of permittivity. In the same way, conductance is given by the measurement 
of loss factor which is related to dipole loss factor and ionic conductance. Both imaginary 
and real parts are present in complex dielectric constant
2
. 
е* = е' - i е'' or е * = [( е')2 + (е'')2]½   
Where, е' is permittivity, е'' is loss factor, i= imaginary unit, and е* is dielectric constant. 
 6 
 
 
Hendrick, K.B. Planar interdigitated dielectric sensor. Soc.Adv.Mater.Pro.Eng. J. 1983, 19, 1-3. 
Figure 1. Theory of Dielectric Analysis 
Both loss factor and permittivity are frequency and temperature dependent 
responses. Tan delta is the ratio of loss factor and permittivity. Response time is related 
to an electric field, tan delta values are related to molecular mobility, and these are 
related to polarization and relaxation of excited molecules
14
. A curve is plotted against е'' 
and е' known as Cole-Cole plot (Figure 2) which is a semicircular plot in which the 
highest point or peak of the plot is considered the critical frequency at which dispersion 
occurs. Figure 2 shows an example of a Cole-Cole plot of microporous and mesoporous 
materials. When alternating electric field is applied, a very finite time is required for 
alignment of dipoles in the field of alternating electric current. But at higher frequencies, 
dipoles cannot follow the given electric field, and, due to this, dielectric constant falls and 
dispersion is seen in the material. This leads to dipole loss which results to loss factor 
peak
14
. Dispersion is the state in which the particles are dispersed in a continuous phase
 
but in a different state. At low frequencies due to accumulation of charges at the electrode 
 7 
 
interfaces, conduction and interfacial polarization occurs, which leads to a straight line in 
a Cole-Cole plot
2, 15
.
  
At higher frequencies polymers with weak or induced dipoles show 
dispersion. However, in a sample like liquid crystals dispersion occurs at significantly 
higher frequencies. Higher permittivity is seen in liquid samples when compared to 
polymers and chemicals
15
. Sometimes the complex polymers and chemicals have 
different relaxation times. Due to this, they show more than one semicircular arc in the 
plot; therefore, these complexes are analyzed based on different semicircular arcs rather 
than considering a single semicircular arc
2
.   
 
Cheng, Q.; Pavlinel, V.; Lengalova, A.; Li, C.; Belza, T.; Saha, P. Electrorheological Proeprties of New mesoporous 
Material with Conducting Polypyrrole in Mesoporous Silica. Microporous and Mesoporous Materials. 2006, 94, 193-199. 
Figure 2. Cole-Cole plot 
a. Parameters measured by DEA 
The two fundamental characteristics of DEA are capacitance (е') and conductance 
(е'') 5. High frequency permittivity is the capacitance which can also be referred to as 
dielectric constant. The capacitive component of DEA has the ability to store an electrical 
charge, and at low temperatures this component is more prominent
17
. At high 
 8 
 
temperatures, the ability to transfer the electric charge increases as dispersion is seen at 
that temperature, which makes the conductive nature of the material more prominent
18
. 
The three main signals that are reported by DEA are permittivity, loss factor, and tan 
delta. Permittivity, denoted by е' is a measure of the alignment of the dipoles to the 
electric field and is proportional to capacitance. Loss factor, denoted by е'' is energy 
required to align dipoles in electric field and also to move dipoles. Loss factor is 
proportional to conductance
19, 20
. Tan delta is a measure of ratio of the loss factor to 
permittivity. It provides information about molecular mobility and response time to 
electric field
19
. 
Ionic conductivity is one of the properties measured using dielectric analysis. 
Viscosity of the sample affects its ionic conductivity because fluidity is identified by the 
ease with which ionic components can migrate through the sample under the applied 
electric field. Under an applied electric field, the orientation of dipoles will be in the 
direction of the field, and the time taken to align in that direction is considered 
polarization or relaxation time
21, 22
.  
2. Differential Scanning Calorimetry 
A wide range of materials can be analyzed using DSC, which includes plastics, 
polymers, pharmaceuticals, and more. DSC is used to measure the heat flow through the 
sample relative to reference material as a function of temperature or time
1
. The data gives 
information about various properties of the sample, like glass transition temperature (Tg), 
sample purity by melting point, heat capacity (Cp), crystallization temperature (Tc), and 
stability of the drug.  
 9 
 
a. Instrument 
DSC measures the heat flow associated with structure (amorphous and crystalline) 
and changes in structure (transitions) of materials as a function of time and temperature in 
a controlled atmosphere. It also measures the properties like exothermic and endothermic 
reactions which reveal information about the physical and chemical properties of the 
material
23
. The results of the DSC analysis also vary depending on the heating rate, 
isothermal hold, starting temperature, ending temperature, type of purge gas, its flow rate, 
and parameters considered for calibration. To obtain better results, it is advised to start 
and end the experiment below and above the temperature of interest which gives a linear 
baseline on each side of the transition
17
. Heating rate varies based on the type of sample 
analyzed. It may vary from 1 
°
C to 100 
°
C /minute. Frequently used heating rates for 
analysis of pharmaceuticals are 10-20 
°
C /min. Lower heating rates are generally used to 
study the purity of the sample, i.e. 1-2 
°
C /min
3,4, 28
. There are two types of DSC – heat 
flow and power compensation. 
i. Heat flux 
Figure 2 is a schematic representation of a heat flux DSC cell. This cell measures 
change in temperature ∆T, between sample and reference. The heat flux, i.e. providing or 
absorbing the heat from the sample, takes place from a large single furnace present in the 
cell. This type of cell has advantages of better baseline, sample-atmosphere interaction, 
and sensitivity
24
. DSC cell consists of two stages, one for the sample pan and the other 
for the reference pan. Both the reference and sample pans are placed in the DSC cell 
usually in an inert atmosphere with temperature predetermined by the program
12
.  
 10 
 
The DSC cell is considered the heart of a DSC as it is connected to different 
purging gases required depending on the chemistry of the sample, shown in Figure 3. It 
consists of the sample pan and the reference pan. Both are made up of the same material. 
The reference pan is empty and a sample is placed in the sample pan
25
. The DSC cell is 
usually an inert atmosphere which is created by purging the cell with nitrogen gas, but 
gases like hydrogen, helium, or air can also be used based on the type of sample being 
analyzed.  
 
Laye, P.G. Differential Thermal Analysis and Differential Scanning Calorimetry. Principles of Thermal Analysis and Calorimetry. 
Haines, P.J.2002, 55-92. 
Figure 3. cross section of DSC heat flux cell 
ii. Power Compensation 
Different amounts of power are used by different furnaces in order to maintain the 
temperature difference between reference and sample. This is more advantageous as it 
has better resolution and also has faster heating and cooling rates. Figure 4 shows the 
 11 
 
design of a power compensation DSC cell, which includes two platinum heaters that 
independently heat the sample and reference
23
. The temperature difference between both 
of them is measured by a platinum resistance thermometer. The purge gas is allowed to 
contact the sample and reference through the holes in the compartment lids. 
Though there are differences between heat flux and power compensation DSC 
cells, the transition heats are comparable and the fusion and crystallization temperatures 
are the same
12
. 
 
Hatakeyama, T.; Liu, Z. Thermal Analysis. Handbook of Thermal Analysis. 1998, 3-80. 
Figure 4. Schematic representation of DSC power compensation cell 
b. Calibration 
The results obtained from instruments are only reliable when the instrument is 
calibrated properly. Calibration should be done at regular time intervals to verify the 
instrument for its better performance and consistency. Standard methods for calibration 
are provided by American Society for Testing and Materials (ASTM)
1
. Materials like 
 12 
 
indium, tin, and lead are used as standards for calibration of the instrument. Calibration in 
sub-ambient temperatures is done using refrigerated cooling system (RCS), and 
sometimes liquid nitrogen is used, and mentioned metals are used for calibration above 
room temperature. Both heating and cooling cycles are calibrated for better results. 
Following calibration, the enthalpy changes associated with amorphous and crystalline 
phases of the sample and their characteristic temperatures can be measured
14
. In 
calibration, a clean DSC cell and calibration materials of high purity play an important 
role.  
c. Sample preparation 
Sample preparation plays a crucial role in any experiment
3
. DSC pans are made of 
aluminum, platinum, copper, etc which may be a closed pan, open pan, pin hole pan or 
sealed pan based on the type of sample chosen for analysis. Pin hole pans are generally 
used when an experiment goes to higher temperature where there are chances of bursting 
of the pan due to reaction at that high temperature and also to expose the sample to 
reactive gases
4
. When the sample is volatile in nature, closed pans are preferred, while 
sealed pans are preferred to avoid liberation of heat from the sample or its formed 
product.  
Sample size may vary depending on type of sample and its density. The smaller 
the sample size, the smaller the thermal gradient which gives better results. For polymers 
and pharmaceuticals the average size of the sample ranges between 5 mg to 10 mg. For 
loosely packed powder to increase their thermal contact with the pan, they are pressed by 
applying slight pressure. For better analysis of the sample it is evenly spread at the 
bottom of pan such that it is in proper contact with the pan. If the particles of the sample 
 13 
 
are of different sizes and shapes, grinding of the sample is preferred in order to get 
reproducible results
28
.  
d. Component characterization 
DSC is used to characterize different components that occur within the sample 
during the heating process. Table 1 shows the different transitions that can take place 
within the sample. 
Table 1. Transitions observed by DSC curve
15
 
Exothermic Endothermic 
Degradation Degradation 
Condensation Vaporization 
Oxidation Reduction 
Decomposition Decomposition 
Solidification Sublimation 
Solvation Desolvation 
Crystallization Fusion 
Adsorption Deposition 
- Glass transition 
 14 
 
Both exothermic and endothermic transitions can be observed by DSC curve as 
seen in Table 1. These exothermic and endothermic peaks are plotted against temperature 
or time with differential heating rates. An imaginary DSC curve is shown in Figure 5 that 
illustrates the most common transitions. It contains glass transition (Tg) at the beginning, 
exothermic peak of crystallization (Tc), endothermic peak of melting (Tm), enthalpy of 
crystallization (∆Hc), and enthalpy of fusion (∆Hf).  
 
Figure 5. An idealized DSC curve 
e. Melting Point 
Melting point is an endothermic transition in which the solid state of the sample is 
transformed to the liquid state. Heat of fusion (∆Hf), which is accurately attained by DSC 
curve, is the amount of heat absorbed by the sample for its melting from solid to liquid 
state. This melting endothermic peak reveals a number of characteristics of the sample 
 15 
 
being analyzed
18, 26
. This peak gives information about the purity of the compound, as 
well as crystalline and amorphous content of the sample. Shape, width and height of the 
peak are used to determine the purity of the sample
19
. A sharp melting peak is observed 
in pure crystalline materials. Pure amorphous samples do not have any melting peak; they 
have glass transition due to small transition changes due to heat supplied
20
. The onset of 
melting point (To) is considered when the transition begins to deviate from the baseline, 
as seen in Figure 6.  
 
Figure 6. DSC curve of indium 
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3. Thermogravimetric Analysis 
Thermogravimetric analysis measures weight change as a function of temperature, 
time, and atmosphere.  
a. Principle 
TGA is used to measure the amount of weight change with its rate with respect to 
time or temperature in a controlled atmosphere. The major parts of the TGA furnace, a 
thermocouple, and a microgram balance. The TGA furnace can go up to temperature of 
1500 
°
C. TGA uses platinum pans, ceramic pans, aluminum pans, and gold pans for 
analysis. Samples are loaded onto microbalance
1
. The thermocouple will be placed close 
to the sample pan, but care should be taken to see that the thermocouple does not touch 
the sample or pan
5
.  
b. Calibration 
Calibration is a must for every instrument before use for analysis of samples. A 
blank test is performed with an empty pan with the same experimental conditions as is 
used for the sample i.e. purged with gas at 40 mL/min to balance and 60 mL/min to 
furnace, heated from room temperature to 1000 
°
C at a heating rate of 20 
°
C/min. The 
general conditions of the apparatus are given by this blank test. The noisy TGA curve is 
indicative of error, one of the errors is that thermocouple is in contact with the sample 
pan. It may be also due to vibration and shock in the instrument
12
.  
i. Calibration of temperature  
The instrument is first calibrated using curie point temperature and then verified 
using calcium oxalate. Curie metals are used for calibration of TGA having different 
 17 
 
curie temperatures. Calibration is done with the use of permanent magnets and by 
measuring the apparent weight change of the materials
14
. 
ii. Weight calibration 
 The instrument is calibrated for weight before starting the experiment. It uses 
standard reference weights from TGA accessory kit to check the accuracy of TGA 
balance. The instrument must be purged with the same gas that will be used for the 
experiment. An empty tare pan that will be used for the experiment is loaded onto the 
balance. Then, the reference weights are added and removed from the sample pan until 
the weight is in limits and checked to acceptability of weight by the balance. When the 
weight is acceptable, the balance is calibrated.  
iii. Baseline calibration 
The baseline may change due to a presence of volatile matter or might be due to 
residual substance. Baseline calibration is required to ensure if the instrument is clean and 
works properly. It is done by running an empty tarred pan in the same conditions used for 
the experiment to 30 minutes and then heating from room temperature to 1000 
°
C
14
. 
Thermal stability and composition of materials can be predicted by TGA data 
obtained. This is done depending on the weight change that occurred when the sample is 
exposed to higher temperatures which causes evaporation, dehydration, decomposition, 
and oxidation. Calcium oxalate monohydrate can be used for verification of the 
instrument
15
. A typical TGA curve of calcium oxalate monohydrate is shown in Figure 7. 
The weight loss of calcium oxalate monohydrate at different stages can be predicted by 
stoichiometry. The molecular weight of the calcium oxalate monohydrate is 146.064, 
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water is 18.004, carbon monoxide is 28, and carbon dioxide is 43.99. The first weight 
loss is due to water from calcium oxalate monohydrate which gives calcium oxalate, 
shown in Equation 1. The theoretical percentage of water mass loss is 12.3 % (18.004/ 
146.064). The second weight loss (Equation 2) is due to loss of carbon monoxide from 
calcium oxalate which gives calcium carbonate. The theoretical percentage of carbon 
monoxide is 19.2% (28/146.064). From calcium carbonate there is a loss of carbon 
dioxide leaving calcium oxide. The loss of carbon dioxide gives the third weight loss 
whose theoretical percentage is 30.2% (43.99/146.064), shown in Equation 3. 
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Figure 7. TGA curve of calcium oxalate 
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1
st
 Step  
CaC2O4
.
H2O (s)       CaC2O4 (s) + H2O (g).................... (1) 
Calcium oxalate monohydrate            Calcium oxalate 
2
nd
 step 
CaC2O4 (s)       CaCO3 (s) + CO (g)……………….. (2) 
Calcium oxalate         Calcium carbonate 
3
rd
 Step 
CaCO3 (s)        CaO (s) + CO2 (g)……………….. (3) 
Calcium carbonate      Calcium oxide 
D. Amorphous and crystalline nature of drugs 
Drugs can be crystalline or amorphous or a combination of crystalline and 
amorphous. Crystalline solids have a long range molecular order; whereas, amorphous 
solids have short range molecular order. The amorphous form of the drug is more useful, 
as this form has more bioavailability. Based on this availability, new developments can 
be made for poorly soluble drugs
27, 29
. The amorphous and crystalline forms can be 
distinguished by molecular order arrangement
12, 19
. 
Amorphous forms are also known as glassy solids, frustrated systems, and 
disordered systems. As the molecular confirmation is random in these solids, they are 
named disordered systems. The name frustrated system is derived due to symmetry and 
geometric frustration at the molecular level
30
. The amorphous content of the solid also 
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depends on certain physical properties like compatibility, flow property of the API (API 
is the parent drug) or sometimes the excipients specific to the drug used in its preparation. 
This may increase the dissolution property of the solid
31
. During preparation of the solids, 
defects may be created in the crystal structure which increases or decreases the molecular 
mobility of the substance. Due to increase in development of a number of insoluble 
crystalline solids in the pharmaceutical industry, the use of amorphous forms has 
increased. Due to the flexibility of the molecules, amorphous forms are more 
advantageous than crystalline forms. The amorphous forms have high energy which 
increases their solubility and compressibility properties
32
.
  
The advantage of the amorphous forms itself can be disadvantageous. The 
disadvantages of amorphous forms restrict their wide use in pharmaceutical industry. The 
amorphous nature of the solid can be surface or bulk phenomenon, i.e. the surface of the 
material may be crystalline and the bulk of the sample might be amorphous and vise-
versa, which can be identified by its dielectric properties
17, 33
.One of the properties of 
amorphous forms is thermal instability. This property is advantageous because, thermal 
instability increases its solubility. However, the thermal instability property of the 
amorphous forms is also a disadvantage. Amorphous forms are converted to crystalline 
forms by adding hydrophilic additives, but, thermal instability of amorphous solids 
makes them unsuitable for adding any additives as they have the irreversible property of 
converting to metastable crystalline forms, where the metastable form is a less stable 
form of the crystalline form
34
.  
 
  
APIs in amorphous forms have more useful properties compared to crystalline 
forms, like high dissolution rate which allows for high solubility of the drug. High 
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dissolution rate of the amorphous forms is due to the absence of lattice energy
18
.  The 
amorphous forms have high energy levels which makes them less stable when compared 
to crystalline forms
20
. Due to their lower stability, during their preparation, additives like 
crystallization inhibitors are added which are hydrophilic in nature which increase their 
stability by increasing their wetting property
35
. The amorphous form is also advantageous 
in its mechanical properties like elastic modulus. Elastic modulus is the ability of the 
substance to deform when force is applied. As crystalline solids are stiffer than 
amorphous forms, they have higher elastic modulus
36
. 
The crystalline forms can be converted into amorphous forms using milling 
technology, hot-melt technology, and also using solvent evaporation method
37
. The 
easiest method is the solvent method where a solvent is added as an additive which 
dissolves the crystalline form of the solid without leaving any residue. If any form of 
crystal is left then it again causes crystallization of the drug by the process of 
nucleation
38
. The crystalline forms have characteristic melting points which can be 
determined by DSC, but the amorphous are characterized by their glass transition 
temperatures as they do not have any melting peak
8
.  
The amorphous forms are brittle below the glass transition temperature, and they 
are in a rubbery state above the glass transition temperature
15
.
 
At the glass transition 
temperature, the amorphous solid loses its thermal energy
39
. A calibration curve is 
prepared from which the crystalline content can be calculated using the equation
13, 14, 18
. 
Riga’s group and other groups like Bansal’s group used the equation below to determine 
the percentage of crystallinity in the sample
34, 11
. 
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Where, Xc is percent of crystallinity, ∆H is the heat of fusion of the sample and ∆Ho is 
that of the 100% crystalline standard. 
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II. MATERIALS AND METHODS 
 
The drugs analyzed were Lidocaine, Procainamide, Ketoconazole and Nifedipine. 
These drugs were obtained from Dr. Alan Riga of Case Western Reserve University. 
These drugs were of ≥98% pure and were used as-received. 
 
Figure 8. Chemical structure of Lidocaine 
 
 
 
 
Figure 9. Chemical structure of Procainamide 
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Figure 10. Chemical structure of Ketoconazole 
 
 
 
 
Figure 11. Chemical structure of Nifedipine. 
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Table 2. List of drugs studied. 
Drug Phase 
Melting 
Point (
◦
C) 
Source Functional Category 
Lidocaine Solid 68-70 
Sigma 
Aldrich 
Local anesthetic and 
antiarrhythmic 
Nifedipine Solid 172-174 
MP 
Biomedicals, 
LLC 
Antianginal and 
antihypertensive 
Procainamide Solid 165-168 
Sigma 
Aldrich 
Antiarrhythmic 
Ketoconazole Solid 146-150 Spectrum Antifungal 
 
A. Dielectric Thermal Analysis 
The dielectric analyzer used for analysis of samples was DEA 2970 by TA 
Instruments. Gold plated ceramic parallel plate sensors and ceramic interdigitated single 
surface gold plated sensors were used for the study. Figures 12 and 13 show the 
interdigitated single surface sensor and gold plated parallel plate sensor used for analysis. 
The instrument was first calibrated. Two types of calibration were done. They are 
electronics calibration and sensor calibration. Electronic calibration was done using 
seven-position internal calibration fixture and two-position internal calibration fixture 
provided by TA Instruments. Sensor calibration was performed each time a new sensor 
was installed to make sure that the sensor to be used was clean. Once the sensor 
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calibration was completed, benzoic acid was used to verify the instruments performance 
and repeatability at least once every 2 weeks, and then the samples were analyzed by 
placing the sample on the electrode. Sample size of 15-20 mg was used and the analysis 
was started according to the required specifications. The samples were studied by 
scanning dielectric analyzer where the samples are heated to 30 °C above the melting 
point as determined by DSC. Throughout the entire study, the instrument was purged 
with nitrogen gas which helps to maintain the inertness in the chamber with a heating rate 
of 10 °C /min. Ionic conductivity at frequencies of 0.1 Hz, 0.5 Hz, 10 Hz, 100 Hz, 1000 
Hz, and 10000Hz was determined. 
 
 
 
 
Figure 12. Interdigitated single plate sensor 
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Figure 13. Gold plated parallel plate sensor 
B. Differential Scanning Calorimetry 
DSC 2920 by TA Instruments was used for analysis of samples in this study. 
Heat-cool-heat method was used for analyzing the samples. The instrument was purged 
with nitrogen gas at a flow rate of 50 mL/min. Aluminum pans were used. Sample size of 
5-10 mg was used. The samples were first equilibrated to -60 °C using refrigerated 
cooling system. Then, the sample is heated to TGA temperature i.e. onset of 1
st
 
decomposition temperature, at a heating rate of 10 °C. Then, it is cooled to 0 °C at a 
heating rate of 2 °C.  It is again heated to the same temperature as in 1
st
 step at a heating 
rate of 10 °C. DSC measures the difference in heat flow rate (mW = mJ/sec) between a 
sample and inert reference as a function of time and temperature
1, 5
. 
The instrument was first calibrated and verified using indium. To test the 
repeatability of the instrument, verification was done five times using indium, and Figure 
14 shows the overlay of 5 runs of Indium. Table 3 summarizes the DSC data of indium 
which is tested for instruments repeatability. For analysis of the samples, aluminum pans 
were used, and a sample size of ~10 mg was used. Samples were heated to 20 °C above 
the melting point with a heating rate of 10 °C/min. The cell was purged with nitrogen gas 
in order to maintain the inertness of the cell.  
 28 
 
Table 3. Analysis of DSC data of Indium 
Sample ID Onset of melting 
temperature (°C) 
Heat of Fusion (J/g) 
Indium run 1 156.5 23.6 
Indium run 2 156.6 23.6 
Indium run 3 156.5 23.6 
Indium run 4 156.9 23.6 
Indium run 5 156.5 23.6 
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C. Thermogravimetric Analysis 
TGA 2950 by TA instruments was used for analysis of the samples. The 
instrument was first verified using calcium oxalate monohydrate. Calcium oxalate 
monohydrate was run for five times to test the repeatability of the instrument. Figure 15 
shows the overlay of calcium oxalate runs. Platinum pans were used to analyze the 
samples. The samples were kept isothermally at room temperature for 30 minutes and 
then heated from room temperature to 1000 °C using a heating rate of 10 °C/min. All the 
experiments were carried out in an inert nitrogen atmosphere with a flow rate of 40 
mL/min to balance and 60 mL/min to furnace. Table 4 summarizes the TGA weight loss 
and DTG peak analysis of Calcium oxalate which is tested to instrument repeatability.  
Table 4. TGA weight loss and DTG peak analysis 
Sample ID 
(Calcium 
Oxalate) 
Weight Loss (%) DTG peak (°C) at weight loss 
1
st
 2
nd
 3
rd
 1
st
 2
nd
 3
rd
 
Run 1 12.1 18.6 30.1 165.6 489.4 733.5 
Run 2 12.2 18.7 30.0 164.2 490.8 734.8 
Run 3 12.4 18.6 30.0 164.5 489.4 733.5 
Run 4 12.4 18.7 30.0 164.2 490.8 734.8 
Run 5 12.4 18.6 30.0 164.4 489.5 733.5 
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III. RESULTS AND DISCUSSION 
 
A. TGA 
TGA instrument was tested for repeatability of the instrument by running calcium 
oxalate monohydrate five times and calculating the standard deviation. The standard 
deviation was found to be around 0.14 for weight loss and 0.7 for decomposition 
temperatures. The values of standard deviation for DTG peaks and weight loss are listed 
in Table 5. TGA curves show the weight change of the drug throughout the temperature 
range. All the samples are decomposed in the nitrogen atmosphere leaving almost no 
residue. From the TGA data, the weight loss of the drugs can be determined. Lidocaine 
and Nifedipine show only one weight loss leaving approximately no residue. From Figure 
16, it is clear that Lidocaine has only one weight loss leaving no residue at the end of the 
experiment. Lidocaine loses 100% of its weight at DTG temperature of 212 
°
C which is 
peak centered. Figure 17 shows the weight loss of Nifedipine. It has two weight losses at 
283 
°
C, where it loses around 97% and at 2
nd
 weight loss it loses around 3% of remaining 
weight, leaving no residue. Figure 18 shows the TGA curve of Ketoconazole which has 
two weight losses, 1
st
 weight loss was around 355 
°
C and 2
nd
 weight loss around 570 
°
C 
where all temperatures are peak centered. Ketoconazole loses 53% of its initial weight, 
and then it loses 48% of its weight, leaving no residue at the end of the experiment. 
Figure 19 shows the weight loss of Procainamide which has three weight losses of 50%, 
27% and 24% at temperatures 295 
°
C, 376 
°
C, and 578 
°
C. All the TGA temperatures are 
peak centered. The TGA temperature of 1
st
 weight loss was used to determine the 
conditions to run DSC experiments. Table 6 summarizes TGA data of all the drugs 
analyzed. 
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Table 5. Standard deviation of TGA curves of Calcium oxalate monohydrate. 
Sample ID 
(Calcium 
Oxalate) 
Weight Loss (%) DTG peak (°C) at weight loss 
1
st
 2
nd
 3
rd
 1
st
 2
nd
 3
rd
 
Run 1 12.1 18.6 30.1 165.6 489.4 733.5 
Run 2 12.2 18.7 30.0 164.2 490.8 734.8 
Run 3 12.4 18.6 30.0 164.5 489.4 733.5 
Run 4 12.4 18.7 30.0 164.2 490.8 734.8 
Run 5 12.4 18.6 30.0 164.4 489.5 733.5 
Standard 
Deviation 
0.14 
 
0.05 
 
0.04 
 
0.58 
 
0.74 
 
0.71 
 
Table 6. Summary of TGA data 
Sample 
 ID 
1
st
 Weight 
Loss (%) 
Temperature 
(
°
C) 
2
nd
 Weight 
Loss (%) 
Temperature 
(
°
C) 
Residue 
(mg) 
Lidocaine 100 212 - - 0 
Nifidipine 97 283 3.0 - 0 
Ketoconazole 53 355 48 571 0 
Procainamide 50 295 27 376 0 
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B. DSC 
The instrument was first tested for its repeatability by running indium five times 
and then standard deviation for peak temperature and enthalpy was calculated. The 
standard deviation was found to be 0.01 for onset of melting temperature and 0.005 for 
heat of fusion, which indicates that the instrument is more accurate. The values of 
standard deviation are listed in Table 7. DSC is used to determine the heat flow which 
allows measurement of glass transition temperature, melting point (endotherm), and 
crystallization temperature (exotherm). DSC heat-cool-heat method was used for 
analysis. Figure 20 shows the DSC curve of Nifedipine, in which glass transition is seen 
at 56 °C. The glass transition is seen during second heating of the sample. The glass 
transition is the significant transition as it causes significant changes in physical and 
reactive changes in the material due to significant changes in molecular mobility. The 
endothermic peak gives the melting temperature of Nifedipine at 173 °C. Figure 21 
shows the DSC curve of Ketoconazole for which glass transition temperature is seen at 
46 °C with melting temperature at 152 °C.  For Ketoconazole also glass transition is seen 
during second heating. Figure 22 shows DSC curve of Procainamide with glass transition 
and melting peak at 44 °C and 172 °C respectively. Figure 23 shows DSC curve for 
Lidocaine. This is the only drug in which recrystallization of the sample is seen 
prominently. Lidocaine does not have any glass transition during second heating also. 
Nifedipine and Lidocaine have considerable melting peak during second heating also 
which is not seen in other samples. Table 8 summarizes the DSC data. 
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Table 7. Standard deviation values for DSC peak of Indium. 
Sample ID Onset of melting temperature 
(°C) 
 
Heat of Fusion (J/g) 
 
 
Indium run 1 
 
156.47 
 
23.6 
 
Indium run 1 
 
156.45 
 
23.6 
 
Indium run 1 
 
156.47 
 
23.59 
Indium run 1 
 
156.48 
 
23.59 
Indium run 1 
 
156.47 
 
23.6 
 
Standard deviation 0.01 
 
0.005 
Table 8. Summary of DSC data.  
Sample Glass transition 
temp (
°
C) 
Onset of 
melting 
temperature 
(
°
C) 
Enthalpy (J/g) Melting Peak 
temp (
°
C) 
Ketoconazole 46 148 107 152 
procainamide 44.0 169 102 172 
Nifidepine 56 155 773 173 
Lidocaine - 67 1565 70 
 
 40 
 
  
1
7
3
.°
C
 
1
5
5
.°
C
 
7
7
3
.J
/g
 
5
6
.°
C
(H
)
 
-2
.0
 
-1
.5
 
-1
.0
 
-0
.5
 
0
.0
 
0
.5
 
Heat Flow (W/g)
 
-1
0
0
 
-5
0
 
0
 
5
0
 
1
0
0
 
1
5
0
 
2
0
0
 
T
e
m
p
e
ra
tu
re
 (
°
C
)
 
S
a
m
p
le
: 
n
if
e
d
ip
in
e
 
S
iz
e
: 
 8
.5
5
0
0
 m
g
 
D
S
C
 
F
il
e
: 
E
:\
re
s
e
a
rc
h
\D
S
C
\n
if
e
d
ip
in
e
 r
-1
.0
0
1
 
O
p
e
ra
to
r:
 u
s
h
a
 
R
u
n
 D
a
te
: 
1
1
-A
p
r-
2
0
1
3
 0
9
:5
2
 
In
s
tr
u
m
e
n
t:
 2
9
2
0
 M
D
S
C
 V
2
.4
F
 
E
x
o
 U
p
 
U
n
iv
e
rs
a
l 
V
4
.3
A
 T
A
 I
n
s
tr
u
m
e
n
ts
F
ig
u
re
 2
0
. 
D
S
C
 c
u
rv
e 
o
f 
N
if
ed
ip
in
e 
 
 41 
 
  
 
 
1
5
2
.°
C
 
1
4
8
.°
C
 
1
0
7
.J
/g
 
4
6
.°
C
(H
)
 
-4
 
-3
 
-2
 
-1
 
0
 
1
 
Heat Flow (W/g)
 
-1
0
0
 
-5
0
 
0
 
5
0
 
1
0
0
 
1
5
0
 
2
0
0
 
2
5
0
 
3
0
0
 
T
e
m
p
e
ra
tu
re
 (
°
C
)
 
S
a
m
p
le
: 
k
e
to
c
o
n
a
z
o
le
 
S
iz
e
: 
 8
.8
5
0
0
 m
g
 
D
S
C
 
F
il
e
: 
E
:.
..
\D
S
C
\k
e
to
c
o
n
a
z
o
le
 2
0
1
2
1
0
2
7
.0
0
1
 
O
p
e
ra
to
r:
 u
s
h
a
 
R
u
n
 D
a
te
: 
2
7
-O
c
t-
2
0
1
2
 1
7
:1
2
 
In
s
tr
u
m
e
n
t:
 2
9
2
0
 M
D
S
C
 V
2
.4
F
 
E
x
o
 U
p
 
U
n
iv
e
rs
a
l 
V
4
.3
A
 T
A
 I
n
s
tr
u
m
e
n
ts
F
ig
u
re
 2
1
. 
D
S
C
 c
u
rv
e 
o
f 
K
et
o
co
n
a
zo
le
 
 
 42 
 
  
1
7
2
.°
C
 
1
6
9
.°
C
 
1
0
2
.J
/g
 
4
4
.°
C
(H
)
 
-4
 
-3
 
-2
 
-1
 
0
 
1
 
Heat Flow (W/g)
 
-1
0
0
 
-5
0
 
0
 
5
0
 
1
0
0
 
1
5
0
 
2
0
0
 
2
5
0
 
T
e
m
p
e
ra
tu
re
 (
°
C
)
 
S
a
m
p
le
: 
p
ro
c
a
in
a
m
id
e
 
S
iz
e
: 
 9
.2
2
0
0
 m
g
 
D
S
C
 
F
il
e
: 
E
:.
..
\D
S
C
\p
ro
c
a
in
a
m
id
e
 2
0
1
2
1
0
2
2
.0
0
1
 
O
p
e
ra
to
r:
 u
s
h
a
 
R
u
n
 D
a
te
: 
2
2
-O
c
t-
2
0
1
2
 1
5
:5
5
 
In
s
tr
u
m
e
n
t:
 2
9
2
0
 M
D
S
C
 V
2
.4
F
 
E
x
o
 U
p
 
U
n
iv
e
rs
a
l 
V
4
.3
A
 T
A
 I
n
s
tr
u
m
e
n
ts
F
ig
u
re
 2
2
. 
D
S
C
 c
u
rv
e 
o
f 
P
ro
ca
in
a
m
id
e
 
 43 
 
  
6
7
.°
C
 
1
5
6
5
.J
/g
 
7
0
.°
C
 
-4
 
-2
 
0
 
2
 
4
 
6
 
8
 
1
0
 
Heat Flow (W/g)
 
-8
0
 
-6
0
 
-4
0
 
-2
0
 
0
 
2
0
 
4
0
 
6
0
 
8
0
 
1
0
0
 
T
e
m
p
e
ra
tu
re
 (
°
C
)
 
S
a
m
p
le
: 
li
d
o
c
a
in
e
 r
-1
 
S
iz
e
: 
 8
.5
5
0
0
 m
g
 
D
S
C
 
F
il
e
: 
E
:\
re
s
e
a
rc
h
\D
S
C
\l
id
o
c
a
in
e
 r
-1
.0
0
1
 
O
p
e
ra
to
r:
 u
s
h
a
 
R
u
n
 D
a
te
: 
1
0
-A
p
r-
2
0
1
3
 1
2
:5
8
 
In
s
tr
u
m
e
n
t:
 2
9
2
0
 M
D
S
C
 V
2
.4
F
 
E
x
o
 U
p
 
U
n
iv
e
rs
a
l 
V
4
.3
A
 T
A
 I
n
s
tr
u
m
e
n
ts
F
ig
u
re
 2
3
. 
D
S
C
 c
u
rv
e 
o
f 
L
id
o
ca
in
e 
 
 44 
 
C. DEA 
DEA is used to determine the ionic conductivity in the sample. Both surface 
analysis and bulk analysis were done on the sample using frequency range of 0.1, 0.5, 
1.5, 10, 100, 500, 1000Hz. Single surface sensor is used for surface analysis of the drugs 
while parallel plate sensor is used for bulk analysis of sample
14
. Figures 24, 26, 28 and 30 
show single surface sensor DEA curves of Ketoconazole, Procainamide, Lidocaine and 
Nifedipine respectively, in which an increase in ionic conductivity at premelt region (10-
30 
◦
C is below its melting point) is observed at 0.1 Hz and 1000 Hz frequencies. Figures 
25, 27, 29 and 31 represent DEA curves analyzed with parallel plate sensor of 
Ketoconazole, Procainamide, Lidocaine and Nifedipine, respectively. In parallel plate 
sensor increase in ionic conductivity is seen only at 1000 Hz frequency except for 
Nifedipine which shows an increase in ionic conductivity at both 0.1 and 1000 Hz 
frequency. Table 9 summarizes DEA data with single surface sensor and Table 10 
summarizes DEA data with parallel plate sensor. The differences in temperatures noted 
on the figures and in the tables are not representative of an actual shift in temperature of 
the ionic conductivity increases at those frequencies, but are a result of the linear heating 
rate that was used to heat the sample. The instrument scans through the frequencies while 
the sample is being heated, which results in an apparent shift in temperature of the 
responses as a function of frequency. The shift occurs at the earliest observed 
temperature, regardless of frequency. 
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Table 9. Summary of DEA data with single surface sensor 
Sample name Frequency of 0.1 Hz Frequency of 1000 Hz 
Temperature(
°
C) 
at the onset of 
increase in log 
ionic 
conductivity 
Log ionic 
conductivity 
(pmho/cm) 
that 
temperature 
Temperature(
°
C) 
at the onset of 
increase in log 
ionic 
conductivity 
Log ionic 
conductivity 
(pmho/cm) 
that 
temperature 
Ketoconazole 143 18.4 138 59.0 
Procainamide 149 50.0 143 159.3 
Lidocaine 64 13.6 59 25.3 
Nifedipine 156 23.5 151 73.7 
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Table 10. Summary of DEA data with parallel plate sensor 
Sample name 
Frequency of 0.1 Hz Frequency of 1000 Hz 
Temperature(
°
C) 
at the onset of 
increase in log 
ionic 
conductivity 
Log ionic 
conductivity 
(pmho/cm) 
that 
temperature 
Temperature(
°
C) 
at the onset of 
increase in log 
ionic 
conductivity 
Log ionic 
conductivity 
(pmho/cm) 
that 
temperature 
Ketoconazole 149 0.27 132 16.01 
Procainamide 169 1.3 173 22.6 
Lidocaine 63 0.13 67 16.3 
Nifedipine 176 0.12 169 7.1 
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All of the drugs tested show an increase in ionic conductivity prior to melt and 
also during melt. TGA is used to determine the weight change as a function of time and 
temperature. The temperature of the first weight loss was used to determine DSC terminal 
temperature. DSC heat-cool-heat method was used for analysis. This method helps to 
know about the amorphous and crystalline content in the drug, as it relates to ionic 
conductivity. The first heating converts the crystalline form of the drug to amorphous 
form. Then, a slow cooling rate was used to maximize the ability of the sample to 
recrystallize thermally. The amount of the sample that recrystallizes depends on specific 
drug properties like the bonds that exist in the sample. The crystalline content and 
amorphous content of the cooled sample is examined by heating it again, which can be 
observed by glass transition and melting peak. 
Glass transitions are only seen in amorphous samples. During the first heating, the 
sample started to melt and endothermic melting peak was observed. When the samples 
were allowed to cool at a slower rate, Lidocaine completely recrystallized, as it does not 
show any glass transition during its second heating also. For Ketoconazole, 
Procaianmide, and Nifedipine, glass transitions were observed during second heat of the 
sample, with only small melting peak. This indicates that the drugs were not able to 
recrystallize completely, or not at all, even with the slow heating rate.  
Parallel plate sensor is used for bulk analysis of dielectric properties of drugs. 
Here, the signal created in the sample has the ability to penetrate into bulk of the sample     
which allows measurement of bulk dielectric properties. The lower sensor i.e. electrode 
applies the voltage in the sample (excitation electrode) which polarizes the sample. The 
polarization of sample creates current in it which is in turn measured by upper electrode 
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(response electrode). As both excitation and response electrode are present on lower and 
upper electrode respectively, the signal should pass through bulk of sample for 
measurement of current. Due to this parallel plate sensor is used for bulk analysis of 
samples.  
The single plate sensor is generally used for analysis of surface dielectric 
properties as signal created in the sample can penetrate only the surface of the sample 
being analyzed
22
. The depth of electrical penetration depends on the width of the 
electrodes
21
. In the single surface sensor, one of the interdigitated comb acts as excitation 
electrode and the current is measured through another interdigitated comb which acts as 
response electrode. As both excitation and response electrodes are present on single 
surface, the signal just passes over the surface of the sample without going into the bulk 
of the sample. Due to this ceramic single surface sensor is used for surface analysis.  
The analysis of samples using single surface sensor gave different results when 
compared with results from parallel plate sensor. From the data of single surface sensor, 
at 0.1 Hz frequency, there is increase in log ionic conductivity at 15-20 °C before the 
melting point i.e. at their pre-melt region. However, in parallel plate sensor increase in 
log ionic conductivity is seen at 0.1 Hz and 1000 Hz frequency. 
The single surface sensor is generally used for surface analysis of samples. 
Increase in log ionic conductivity is observed even at 0.1 Hz and also at 1000 Hz 
frequency.  Among the drugs chosen for analysis, Procainamide has higher ionic 
conductivity. And, also increase in log ionic conductivity in pre-melt region is seen at 15 
°
C below its melting point. As Lidocaine has lower ionic conductivity when analyzed 
 57 
 
using single surface sensor, it can be said that it is due to more crystallinity in nature 
which has restricted movement of the ions and dipoles. For procainamide also, ionic 
conductivity in pre-melt region is observed. The frequencies of the analysis in DEA 
considered are for both surface analysis and bulk analysis.  
The 100 Hz frequency is considered as break point between surface analysis and 
bulk analysis
21
. The frequencies less than break point frequency are considered for 
surface analysis of sample and above that are considered for bulk analysis. The ionic 
conductivity in pre-melt temperature regions might be due to presence of water content, 
movement of ions, impurities, secondary relaxations present in molecules or that may 
arise when small amounts of heat are given.  
Figures 32, 33, 34, and 35 shows overlay of DSC and DEA curves of 
Ketoconazole, Lidocaine, Nifedipine, and Procainamide from which it is clear that 
increase in log ionic conductivity was observed both at pre melt temperature region (15-
20 °C) and also during its melting. The onset of melting was observed at 148 °C and the 
increase in log ionic conductivity was observed 15- 20 °C before the onset of melting i.e. 
at premelt region. The log ionic conductivity in pre-melt region increased to 10
2
-10
5
 
pmho/cm. The polarization of the material allows the dipoles to align in direction of 
applied field, which in turn allows measuring the conductivity of the sample. The same is 
applicable for all other drugs in which increase in log ionic conductivity is seen at pre-
melt and melt regions.  
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Figure 32. Overlay of DSC and DEA curves of Ketoconazole (Green-DEA curve, 
Blue-DSC curve) 
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Figure 33. Overlay of DSC and DEA curves of Lidocaine (Green-DEA curve, Blue-
DSC curve) 
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Figure 34. Overlay of DSC and DEA curves of Nifedipine (Green-DEA curve, Blue-
DSC curve) 
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Figure 35. Overlay of DSC and DEA curves of Procainamide (Green-DEA curve, 
Blue-DSC curve) 
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IV. CONCLUSION 
This research was done to study the dielectric behavior of drugs under applied 
external electric field and comparing the results of parallel plate and single surface 
sensors. The results obtained from DEA show that there are unique variations in log ionic 
conductivity at pre-melt regions at 15 -20 
°
C below its melting point. All the drugs show 
an increase in log ionic conductivity at pre-melt region.  
Increase in log ionic conductivity is seen with single surface sensor as well as 
parallel plate sensor, from which it can be concluded that increase in log ionic 
conductivity is a bulk phenomenon not just a surface phenomenon. Lidocaine was the 
only drug tested that could recrystallize thermally. 
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